22 completed, 22 terminated, 5 active not recruiting, 4 unknown. 38 Phase 1, 25 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow PDR001: new trials by email Literature Review of PDR001 trials Research Report on PDR001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease PDR001 - Parkinson Disease (PD) | Phase 1 | Recruiting | Ruijin Hospital | 12 | 2025-10-20 | 2025-09-05 |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. decitabine, spartalizumab, sabatolimab - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 33 | 2023-02-28 | 2026-09-22 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 90 | 2022-03-22 | 2023-02-03 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NIS793, Spartalizumab, gemcitabine - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 164 | 2020-10-16 | 2025-10-16 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2020-08-19 | 2024-10-09 |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Dabrafenib, LTT462, Trametinib - BRAF V600 Colorectal Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2020-07-22 | 2025-12-24 |
| Ribociclib and Spartalizumab in R/M HNSCC Ribociclib, Spartalizumab - Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | National Taiwan University Hospital | 13 | 2020-03-13 | 2022-04-21 |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab NIZ985, Spartalizumab, Tislelizumab - In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 60 | 2020-02-27 | 2025-05-06 |
| KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors KAZ954, PDR001, NIR178 - Solid Tumors | Early Phase 1 | Terminated | Novartis Pharmaceuticals | 77 | 2020-02-20 | 2025-05-18 |
| Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus PDR001 - Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment | Phase 2 | Unknown | Yonsei University | 44 | 2020-02-18 | 2021-05-06 |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery - Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-01-29 | 2024-10-30 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Siltuximab, Spartalizumab - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | Emory University | 35 | 2020-01-17 | 2025-08-22 |
| Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments PDR001 - Advanced Solid Tumors | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 120 | 2019-10-30 | 2026-07-28 |
| PDR001 + Panobinostat for Melanoma and NSCLC PDR001, Panobinostat - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Withdrawn | Muhammad Furqan | 2019-09-01 | 2019-10-04 | |
| Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies TNO155, Spartalizumab, Ribociclib - Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2019-07-30 | 2025-09-30 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. DKY709, PDR001 - Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 98 | 2019-05-07 | 2026-10-19 |
Showing 20 of 57. Sign in to see all of them.
Melanoma (15) · Carcinoma, Non-Small-Cell Lung (14) · Triple Negative Breast Neoplasms (12) · Colorectal Neoplasms (8) · Carcinoma, Renal Cell (6) · Pancreatic Neoplasms (5) · Lymphoma (4) · Neoplasm Metastasis (4) · Adenocarcinoma Of Esophagus (3) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Liver Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Adenocarcinoma (2) · Adenocarcinoma of Lung (2)
Novartis Pharmaceuticals (45) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Muhammad Furqan (1) · National Taiwan University Hospital (1) · Ruijin Hospital (1) · SOLTI Breast Cancer Research Group (1) · Yonsei University (1)
United States (45) · Spain (37) · Italy (30) · Germany (29) · Japan (26) · Canada (24) · France (24) · Taiwan (20) · Singapore (19) · Belgium (16) · Netherlands (16) · Australia (15) · South Korea (14) · Hong Kong (13) · Switzerland (12)
Alan L Ho, MD, PhD (1) · Byoung Chul Cho (1) · Hsiang-Fong Kao, MD (1) · Muhammad Furqan, MD (1) · Nancy Lewis, MD (1) · Nehal Parikh, MD (1) · Olatunji Alese, MD (1) · Rodabe N Amaria (1) · Ryan Corcoran, MD (1) · Sara Tolaney, MD (1)
PMID 25614940, PMID 29474450, PMID 30832732, PMID 32179633, PMID 32364844, PMID 32823563, PMID 33020648, PMID 33883177, PMID 33941878, PMID 34389618, PMID 34433653, PMID 34799399, PMID 35030011, PMID 35217575, PMID 35655320, PMID 35728875, PMID 36200668, PMID 36702949, PMID 36969745, PMID 37907221, PMID 38030303, PMID 38336861, PMID 38617599, PMID 38721402, PMID 38919826, PMID 39209782, PMID 39448966, PMID 42585631
2016 (9), 2015 (7), 2017 (5), 2018 (5), 2019 (4), 2014 (2), P30CA138292 (1)